In this project, intensive care unit (ICU) patients treated with beta-lactam antibiotics are included with the aim to investigate the potential underdosing in this patient group. Four regional ICU-clinics are recruiting consecutive patients (n=120) and samples are taken before the next dose is administered for three consecutive days.
Study Type
OBSERVATIONAL
Enrollment
120
Intensive care unit
Jönköping, Jönköping County, Sweden
Intensive Care Unit
Kalmar, Kalmar County, Sweden
Intensive Care Unit
Linköping, Linköping, Sweden
Intensive care unit
Vaxjo, Växjö, Sweden
The rate of patients below 16mg/L for piperacillin-tazobactam, 2 mg/L for meropenem and 4mg/L for cefotaxim
Time frame: 3 days
Mortality in relation to initial levels of beta-lactam antibiotics as defined in primary outcome
Time frame: 30 days
The rate of patients below 100% time over MIC in relation to the bacteria causing the infection.
Time frame: 3 days
Kidney function measured as eGFR in relation to initial levels of beta-lactam antibiotics as defined in primary outcome
Time frame: 3 days
SAPS-score in relation to initial levels of beta-lactam antibiotics as defined in primary outcome
Time frame: 3 days
Days in intensive care unit in relation to initial levels of beta-lactam antibiotics as defined in primary outcome
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.